Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Neumora Therapeutics, Inc. Common Stock

NMRA

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Last trade $0.3081
Day change -$0.0614 (-16.62%)
Day range $0.304 – $0.426
Volume 1,362,268
Market cap $69M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$69.52M
Price / earnings
—
Price / book
1.56×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.03×

Profitability

Earnings per share
-$1.13
Return on assets
-169.86%
Return on equity
-477.87%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.19×
Current ratio
4.5×
Quick ratio
4.5×
Cash ratio
4.21×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$180.52M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NMRA, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$12.91M$14.27M$13.81M$12.18M$15.32M$18.79M$17.01M$16.02M
Research and development$29.28M$38.6M$44.67M$45.52M$38.72M$52.15M$45.91M$60.63M
Total operating expenses$42.19M$52.86M$58.48M$57.7M$54.04M$70.94M$62.92M$76.65M
Operating income-$42.19M-$52.86M-$58.48M-$57.7M-$54.04M-$70.94M-$62.92M-$76.65M
Interest expense-$1.82M-$1.85M-$2.04M-$747K-$436K$0$0$0
Income before taxes-$43.08M-$53.43M-$59.45M-$56.76M-$52.71M-$67.89M-$58.82M-$72.49M
Income taxes$0$30K$0$0$25K$105K$0$53K
Net income-$43.08M-$53.46M-$59.45M-$56.76M-$52.73M-$67.99M-$58.82M-$72.55M
Net income attributable to common shareholders-$43.08M-$53.46M-$59.45M-$56.76M-$52.73M-$68.06M-$58.82M-$72.55M
EBITDA-$42.18M-$52.86M-$58.47M-$57.68M-$54.02M-$70.78M-$62.77M-$76.49M
Basic earnings per share-$0.23-$0.30-$0.35-$0.35-$0.33-$0.42-$0.37-$0.45
Diluted earnings per share-$0.23-$0.30-$0.35-$0.35-$0.33-$0.42-$0.37-$0.45

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant failed to achieve primary endpoints for major depressive disorder treatment, leading the company to discontinue the program. The company is refocusing on three other clinical programs (NMRA-511, NMRA-898, and NMRA-215) and implementing a 35% workforce reduction to extend cash runway into Q3 2027.

GlobeNewswire Inc.

Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

Neumora Therapeutics announced it will host a conference call on March 30, 2026, to report Q4 and full year 2025 financial results and provide a business update. The clinical-stage biopharmaceutical company highlighted its 2026 pipeline strategy with multiple clinical data readouts expected, including consolidated topline readouts for KOASTAL-2 and -3 trials anticipated in Q2 2026.

GlobeNewswire Inc.

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Neumora Therapeutics, a clinical-stage biopharmaceutical company, announced it will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The company highlighted its 2026 pipeline strategy with multiple clinical data readouts expected, including KOASTAL-2 and -3 trials anticipated for Q2 2026 readout. Additionally, positive Phase 1b results from NMRA-511 in Alzheimer's disease agitation showed a clinically meaningful 15.7-point reduction on the CMAI total score.

Investing.com

Top 3 Biotech Stocks Capitalizing on the AI Revolution

Three clinical-stage biotech companies are leveraging AI to advance drug discovery and treatment in areas like aging, neuroscience, and oncology, with promising platforms that use machine learning to analyze complex biological data.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.